Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2

Trial Profile

A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs NT 501 (Primary)
  • Indications Retinal telangiectasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Neurotech USA
  • Most Recent Events

    • 12 Feb 2019 According to a Neurotech Pharmaceuticals (Neurotech USA) media release, two parallel studies (NCT03319849 and NCT03316300) are sponsored by Neurotech in collaboration with the Lowy Medical Research Institute (LMRI).
    • 12 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top